ALA · ASX

Arovella Therapeutics Limited (ASX:ALA)

AU$0.19

 0.005 (2.703%)
ASX:Live
30/10/2024 03:49:06 PM
HALO Ords GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

ALA Overview

ALA Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About ALA

Website

Arovella Therapeutics Limited

Telephone

61.3.9824.5254

Address

Level 3, Suite 1 62 Lygon Street Carlton South, Victoria (VIC) 3053

Description

Arovella Therapeutics Ltd. engages in the development invariant Natural Killer (iNKT) cell platform for treatment of cancer. Its technologies include iNKT cell therapy, CAR19-iNKT + CF33-CD19, CLDN18.2-iNKT, and DKK1-CAR-iNKT. The company was founded on December 21, 1999 and is headquartered in Carlton South, Australia.

ALA Price Chart

Key Stats

Market Cap

AU$190.12M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.08 - 0.2

Trade Value (12mth)

AU$62,749.00

1 week

5.71%

1 month

19.35%

YTD

54.17%

1 year

103.3%

All time high

14.78

Key Fundamentals

EPS 3 yr Growth

-38.80%

EBITDA Margin

%

Operating Cashflow

-$7m

Free Cash Flow Return

-92.10%

ROIC

-116.60%

Interest Coverage

-1,247.60

Quick Ratio

6.40

Other Data

Shares on Issue (Fully Dilluted)

978m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ALA Announcements

Latest Announcements

Date Announcements

29 October 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

29 October 24

AusBioInvest Presentation

×

AusBioInvest Presentation

25 October 24

Arovella receives R&D tax rebate of $3.0 million

×

Arovella receives R&D tax rebate of $3.0 million

24 October 24

Application for quotation of securities - ALA

×

Application for quotation of securities - ALA

24 October 24

Notice Under Section 708A

×

Notice Under Section 708A

18 October 24

Application for quotation of securities - ALA

×

Application for quotation of securities - ALA

18 October 24

Notice Under Section 708A

×

Notice Under Section 708A

16 October 24

Investor Presentation

×

Investor Presentation

16 October 24

Application for quotation of securities - ALA

×

Application for quotation of securities - ALA

16 October 24

Notice Under Section 708A

×

Notice Under Section 708A

14 October 24

Clinical Advisory Board established

×

Clinical Advisory Board established

09 October 24

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

07 October 24

Notification regarding unquoted securities - ALA

×

Notification regarding unquoted securities - ALA

01 October 24

Release of Shares from Escrow

×

Release of Shares from Escrow

19 September 24

Application for quotation of securities - ALA

×

Application for quotation of securities - ALA

19 September 24

Notification regarding unquoted securities - ALA

×

Notification regarding unquoted securities - ALA

18 September 24

Change in substantial holding

×

Change in substantial holding

18 September 24

Becoming a substantial holder

×

Becoming a substantial holder

18 September 24

Investor Webinar Presentation

×

Investor Webinar Presentation

12 September 24

Investor Webinar Presentation

×

Investor Webinar Presentation

12 September 24

Updated Investor Webinar Presentation

×

Updated Investor Webinar Presentation

11 September 24

2024 ESG Report

×

2024 ESG Report

10 September 24

ALA presents at Cell and Gene Therapy World Asia Conference

×

ALA presents at Cell and Gene Therapy World Asia Conference

22 August 24

Appendix 4E and Annual Report

×

Appendix 4E and Annual Report

22 August 24

Appendix 4G

×

Appendix 4G

ALA Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.02 -0.01 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.02 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -3.3 8.9 35.0 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -44.1 12.2 11.5 Lock Lock Lock
     Yield % Lock Lock Lock Lock -49.9 -18.0 -5.3 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.01 0.00 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.00 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -36.6 -44.5 140.3 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 550 711 941 Lock Lock Lock
Basic m Lock Lock Lock Lock 550 711 941 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 14.9 37.2 -95.8 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 5 7 11 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -2 -3 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -23.0 -26.8 99.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock -800.0 -739.1 -152.8 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 900 839 253 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -7 -9 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -74.6 -25.5 -21.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -2,381.6 -2,178.8 -63,342.8 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 1 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -8 -10 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -62.0 -27.4 -11.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -2,568.0 -2,385.0 -63,595.6 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -9 -11 -11 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 -1 -2 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -9 -10 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock -70.8 -18.1 14.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock -2,914.2 -2,508.4 -51,447.3 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -6 -6 -7 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 1 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -1 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 6 5 15 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -6 -6 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -69.9 -1.5 -10.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -21.3 -15.8 -414.3 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 6 5 13 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 9 5 13 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -6 -5 -13 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 8 4 11 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 8 4 11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -14.4 -50.9 197.0 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -93.6 -186.1 -65.8 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -113.2 -269.3 -77.9 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -90.3 -167.7 -144.1 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -103.4 -177.5 -116.6 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -75.2 -111.5 -92.1 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -36.2 -427.8 -1,247.6 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.8 0.6 1.2 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -77.8 -136.9 -113.2 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 4.4 3.1 6.4 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 4.4 3.1 6.4 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 92.2 99.2 96.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -415.5 -380.4 -338.8 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 1.0 17.4 3.3 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.1 0.1 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 254.2 190.4 5,787.9 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.1 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.1 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -2,914.2 -2,766.7 -62,830.3 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -93.6 -205.3 -80.4 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -93.6 -186.1 -65.8 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.4 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -113.2 -269.3 -77.9 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -113.2 -269.3 -77.9 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 352.0 20.9 110.3 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 352.0 20.9 110.3 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 67.1 81.7 7,464.2 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 284.9 -60.8 -7,353.9 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ALA Shortsell

Frequently Asked Questions

The current share price of Arovella Therapeutics Limited (ALA:ASX) is AU$0.19.
The 52-week high share price for Arovella Therapeutics Limited (ALA:ASX) is AU$0.20.
The 52-week low share price for Arovella Therapeutics Limited (ALA:ASX)? is AU$0.08.
Arovella Therapeutics Limited (ALA:ASX) does not pay a dividend.
Arovella Therapeutics Limited (ALA:ASX) does not pay a dividend.
Arovella Therapeutics Limited (ALA:ASX) has a franking level of 0.0%.
Arovella Therapeutics Limited (ALA:ASX) is classified in the Healthcare.
The current P/E ratio for Arovella Therapeutics Limited (ALA:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.